Abstract: Provided are transgenic mice whose genome comprises a nucleic acid sequence encoding human cereblon (CRBN) or a fragment thereof, wherein endogenous mouse CRBN is not expressed in the transgenic mice. Also provided are cells, cell lines, tissues, and organs derivable from the transgenic mice, and methods for producing and using such mice.

Abstract: Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

Abstract: Methods, systems and computer program products for selectively providing authenticated data corresponding to a payment card holder at a point-of-sale (POS) terminal are described. The method can include receiving from a terminal device, payment card account information comprising a payment card account identifier and user authentication information. Responsive to the received user authentication information matching one of a plurality of predefined authentication keys associated with the payment card account identifier, a predefined function is selected from among at least first and second predefined functions associated with the payment card account identifier—wherein the selection of the predefined function from among the first and second predefined functions is based on an association between the selected predefined function and an authentication key that has been matched with the received user authentication information.

Abstract: Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.

Abstract: Disclosed herein is a compound or pharmaceutically acceptable salts or stereoisomers thereof of of formula I wherein X1 is linear or branched C1-6 alkyl, C3-6 cycloalkyl, —C1-6 alkyl C3-6 cycloalkyl, C6-10 aryl, 5-10 membered heteroaryl, C1-6 alkyl C6-10 aryl, C1-6 alkyl 5-10 membered heteroaryl, wherein X1 is unsubstituted or substituted with one or more of halogen, linear or branched C1-6 alkyl, linear or branched C1-6 heteroalkyl, CF3, CHF2, —O—CHF2, —O—(CH2)2—OMe, OCF3, C1-6 alkylamino, —CN, —N(H)C(O)—C1-6alkyl, —OC(O)—C1-6alkyl, —OC(O)—C1-4alkylamino, —C(O)O—C1-6alkyl, —COOH, —CHO, —C1-6alkylC(O)OH, —C1-6alkylC(O)O—C1-6alkyl, NH2, C1-6 alkoxy or C1-6 alkylhydroxy; X2 is hydrogen, C6-10 aryl, 5-10 membered heteroaryl, —O-(5-10 membered heteroaryl), 4-8 membered heterocycloalkyl, C1-4 alkyl 4-8 membered heterocycloalkyl, —O-(4-8 membered heterocycloalkyl), —O—C1-4 alkyl-(4-8 membered heterocycloalkyl), —OC(O)—C1-4alkyl-4-8 membered heterocycloalkyl or C6 aryloxy, wherein X2 is unsubstituted or substi

Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.

Abstract: The disclosed subject matter includes methods, systems, and networks for authentication based on physical characteristics of a mobile device. A computer-implemented method performed by a payment network includes receiving an image of a part of a mobile device from an image capturing device that communicates with the payment network, wherein the mobile device includes digital card data of a customer. The computer-implemented method may also include comparing a physical condition of the part of the mobile device shown in the received image to the physical condition of the part of the mobile device shown in a stored image. In addition, the computer-implemented method may include authenticating or declining a transaction involving the digital card data based on the comparison of the physical condition of the part of the mobile device in the received image and the stored.

Abstract: Provided herein are methods for treating or preventing a solid tumor, non-Hodgkin lymphoma or multiple myeloma in a patient, comprising administering an effective amount of a TOR kinase inhibitor to a patient having a solid tumor, non-Hodgkin lymphoma or multiple myeloma.

Abstract: Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

Abstract: An integrated circuit (IC) chip for transparent and in-service or production repair of single to multiple memory cell defects in a word during the datapath transit of the word between core memory to the interface of the IC via capturing an accurate bit from a word during a write access to a known defective memory address, and by substituting in a non-defective bit into the word during a read access from a known defective memory address. The IC includes: address matching circuit (CAM), a random access memory (RAM) of substitute memory cells containing accurate associated bit data and bit location in word of defect, and data selection circuitry (MUXs) coupled together.

Abstract: Provided herein, in some embodiments, are methods of using certain cereblon-associated proteins, such as Aiolos, Ikaros, interferon (IFN), and IFN pathway proteins, casein kinase 1, alpha 1 (CSNK1A1), and ZFP9, as biomarkers for use in predicting and monitoring clinical sensitivity and therapeutic response to certain compounds in patients having various diseases and disorders, such as cancers (e.g., diffuse large B-cell lymphoma (DLBCL), multiple myeloma (MM), myelodysplasia syndromes (MDS) and acute myeloid leukemia (AML)) and IFN-associated disorders. Also provided herein, in certain embodiments, are methods of determining the efficacy of an immunomodulatory compound.

Abstract: Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

Abstract: Systems and methods are provided for implementing an interactive loyalty reward program for transactions conducted at transaction terminals, for instance, consumer purchase transactions conducted at a point-of-sale terminal. The system includes a server configured to monitor and identify qualifying transactions under the reward program. The server also coordinates operation of consumer-facing devices accessible to the consumer at the point-of-sale. The consumer-facing devices include an interactive value generator (IVG), which is configured to provide a game-like experience to consumers and interactively generates unspecified reward values for qualifying transactions. A loyalty reward application executing on the transaction terminal is also provided to guide consumer interaction with the IVG and communicate the generated reward values to the server.

Abstract: Provided herein are methods of using compounds and compositions for modulating leukocytic activity, including activity of B cells and/or T cells monocytes, macrophages, and other lymphoid or myeloid-derived cell types, in immune-related diseases or inflammatory diseases. Pharmaceutical compositions and dosing regimens for use in the methods are also provided herein.

Abstract: The disclosed subject matter includes methods, systems, and networks for authentication based on physical characteristics of a mobile device. A computer-implemented method performed by a payment network includes receiving an image of a part of a mobile device from an image capturing device that communicates with the payment network, wherein the mobile device includes digital card data of a customer. The computer-implemented method may also include comparing a physical condition of the part of the mobile device shown in the received image to the physical condition of the part of the mobile device shown in a stored image. In addition, the computer-implemented method may include authenticating or declining a transaction involving the digital card data based on the comparison of the physical condition of the part of the mobile device in the received image and the stored.

Abstract: The disclosed subject matter includes methods, systems, and networks for authentication based on physical characteristics of a payment card. A computer-implemented method performed by a payment network includes receiving an image of a part of a payment card from an image capturing device that communicates with the payment network. The computer-implemented method may also include comparing a physical condition of the part of the payment card shown in the received image to the physical condition of the part of the payment card shown a stored image. In addition, the computer-implemented method may include authenticating or declining a transaction based on the comparison of the physical condition of the part of the payment card in the received image and the stored image.

Abstract: Provided herein are methods for treating or preventing a cancer, comprising administering an effective amount of a TOR kinase inhibitor and an effective amount of an IMiD® immunomodulatory drug to a patient having a cancer.

Abstract: A method for determining a development plan for an area includes receiving input parameters associated with a plurality of target geographical areas and a reference geographical area; identifying, based on the input parameters, a candidate geographical area matching the reference geographical area from the plurality of target geographical areas; and determining a development activity for the candidate geographical area based on an outcome of said development activity in the reference geographical area.

Abstract: Methods, systems and computer program products for selectively providing authenticated data corresponding to a payment card holder at a point-of-sale (POS) terminal are described. The method can include receiving from a terminal device, payment card account information comprising a payment card account identifier and user authentication information. Responsive to the received user authentication information matching one of a plurality of predefined authentication keys associated with the payment card account identifier, a predefined function is selected from among at least first and second predefined functions associated with the payment card account identifier—wherein the selection of the predefined function from among the first and second predefined functions is based on an association between the selected predefined function and an authentication key that has been matched with the received user authentication information.